Advertisement

International Ophthalmology

, Volume 38, Issue 2, pp 781–785 | Cite as

Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis

  • Georgios Makragiannis
  • Kaveh Vahdani
  • Ester Carreño
  • Richard W. J. Lee
  • Andrew D. Dick
  • Adam H. Ross
Case Report

Abstract

Purpose

To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.

Methods

Case report.

Results

A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.

Conclusions

Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.

Keywords

Candida Chorioretinitis Choroidal neovascular membrane Bevacizumab 

Notes

Acknowledgements

RWJL and ADD received funding from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Compliance with ethical standards

Conflicts of interest

None of the authors have any proprietary interest in the materials described in this study.

Ethical standard

This report is limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) and therefore excluded from REC review.

References

  1. 1.
    Lashof AMO, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Oborska IT, Rex JH, Kullberg BJ (2011) Ocular manifestations of candidemia. Clin Infect Dis 53(3):262–268. doi: 10.1093/cid/cir355 CrossRefGoogle Scholar
  2. 2.
    Shah CP, McKey J, Spirn MJ, Maguire J (2008) Ocular candidiasis: a review. Br J Ophthalmol 92(4):466–468. doi: 10.1136/bjo.2007.133405 CrossRefPubMedGoogle Scholar
  3. 3.
    Jampol LM, Sung J, Walker JD, Folk JC, Townsend-Pico WA, Lowder CY, Dodds EM, Westrich D, Terry J (1996) Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am J Ophthalmol 121(6):643–649CrossRefPubMedGoogle Scholar
  4. 4.
    Macular Photocoagulation Study Group (1994) Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 112(4):500–509CrossRefGoogle Scholar
  5. 5.
    Tedeschi M, Varano M, Lomoriello DS, Scassa C, Parisi V (2007) Photodynamic therapy outcomes in a case of macular choroidal neovascularization secondary to Candida endophthalmitis. Eur J Ophthalmol 17(1):124–127CrossRefPubMedGoogle Scholar
  6. 6.
    Recchia FM, Shah GK, Eagle RC, Sivalingam A, Fischer DH (2002) Visual and anatomical outcome following submacular surgery for choroidal neovascularization secondary to Candida endophthalmitis. Retina 22(3):323–329CrossRefPubMedGoogle Scholar
  7. 7.
    Durand ML (2013) Endophthalmitis. Clin Microbiol Infect 19(3):227–234. doi: 10.1111/1469-0691.12118 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sallam A, Taylor SR, Khan A, McCluskey P, Lynn WA, Manku K, Pacheco PA, Lightman S (2012) Factors determining visual outcome in endogenous Candida endophthalmitis. Retina 32(6):1129–1134. doi: 10.1097/IAE.0b013e31822d3a34 CrossRefPubMedGoogle Scholar
  9. 9.
    Doan T, Vemulakonda GA, Choi D, Keene CD, Akileswaran L, Van Gelder RN, Chao JR (2014) Retinal neovascularization and endogenous fungal endophthalmitis in intravenous drug users. Ophthalmology 121(9):1847–1848. doi: 10.1016/j.ophtha.2014.03.037 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dhingra N, Kelly S, Majid MA, Bailey CB, Dick AD (2010) Inflammatory choroidal neovascular membrane in posterior uveitis-pathogenesis and treatment. Indian J Ophthalmol 58(1):3–10. doi: 10.4103/0301-4738.58467 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Coats ML, Peyman GA (1992) Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 12(1):46–51CrossRefPubMedGoogle Scholar
  12. 12.
    Shimada H, Yuzawa M, Hirose T, Nakashizuka H, Hattori T, Kazato Y (2008) Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol 52(4):282–288. doi: 10.1007/s10384-008-0566-2 CrossRefPubMedGoogle Scholar
  13. 13.
    Carreno E, Moutray T, Fotis K, Lee RW, Dick AD, Ross AH, Bailey C (2015) Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. Br J Ophthalmol. doi: 10.1136/bjophthalmol-2015-307806 PubMedGoogle Scholar
  14. 14.
    Tian JX, O’Hagan S (2015) Toxocara polymerase chain reaction on ocular fluids in bilateral granulomatous chorioretinitis. Int Med Case Rep J 8:107–110. doi: 10.2147/IMCRJ.S84185 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lyall DA, Hutchison BM, Gaskell A, Varikkara M (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to ocular toxocariasis in a 13-year-old boy. Eye (Lond) 24(11):1730–1731. doi: 10.1038/eye.2010.131 CrossRefGoogle Scholar
  16. 16.
    Kianersi F, Naderi Beni A, Naderi Beni Z, Ghanbari H (2015) Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series. Semin Ophthalmol 30(3):181–187. doi: 10.3109/08820538.2013.838278 CrossRefPubMedGoogle Scholar
  17. 17.
    Sheu SJ (2009) Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to endogenous endophthalmitis. Kaohsiung J Med Sci 25(11):617–621. doi: 10.1016/S1607-551X(09)70566-2 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Bristol Eye HospitalUniversity Hospitals Bristol NHS Foundation TrustBristolUK
  2. 2.School of Clinical Sciences, Faculty of Medicine and DentistryUniversity of BristolBristolUK
  3. 3.National Institute for Health Research Biomedical Research CentreMoorfields Eye Hospital NHS Foundation Trust and UCL Institute of OphthalmologyLondonUK

Personalised recommendations